243 related articles for article (PubMed ID: 37402960)
1. Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months.
Martinka E; Dravecká I; Tkáč I
Diabetes Ther; 2023 Sep; 14(9):1503-1515. PubMed ID: 37402960
[TBL] [Abstract][Full Text] [Related]
2. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
[TBL] [Abstract][Full Text] [Related]
3. Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.
Oe Y; Nomoto H; Nakamura A; Kuwabara S; Takahashi Y; Yasui A; Izumihara R; Miya A; Kameda H; Cho KY; Atsumi T; Miyoshi H
J Diabetes Res; 2022; 2022():5603864. PubMed ID: 35097130
[TBL] [Abstract][Full Text] [Related]
4. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
[TBL] [Abstract][Full Text] [Related]
6. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
Komatsu M; Watada H; Kaneko S; Ross Agner BF; Nishida T; Kaku K
J Diabetes Investig; 2021 Sep; 12(9):1610-1618. PubMed ID: 33595901
[TBL] [Abstract][Full Text] [Related]
8. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
Front Public Health; 2022; 10():990281. PubMed ID: 36091534
[TBL] [Abstract][Full Text] [Related]
9. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
Wang W; Agner BFR; Luo B; Liu L; Liu M; Peng Y; Qu S; Stachlewska KA; Wang G; Yuan G; Zhang Q; Ning G
J Diabetes; 2022 Jun; 14(6):401-413. PubMed ID: 35762390
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
Risovic I; Dumanovic MS; Bojic M; Djekic D
BMC Endocr Disord; 2023 Feb; 23(1):28. PubMed ID: 36726134
[TBL] [Abstract][Full Text] [Related]
12. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK; Agner BFR; Altuntas Y; Grøn R; Halladin N; Klonoff DC; Tentolouris N; Jódar E
J Diabetes Sci Technol; 2021 May; 15(3):636-645. PubMed ID: 32107930
[TBL] [Abstract][Full Text] [Related]
13. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Gough SC; Bode BW; Woo VC; Rodbard HW; Linjawi S; Zacho M; Reiter PD; Buse JB
Diabetes Obes Metab; 2015 Oct; 17(10):965-73. PubMed ID: 25980900
[TBL] [Abstract][Full Text] [Related]
14. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
15. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
Holst JJ; Buse JB; Rodbard HW; Linjawi S; Woo VC; Boesgaard TW; Kvist K; Gough SC
J Diabetes Sci Technol; 2015 Oct; 10(2):389-97. PubMed ID: 26443290
[TBL] [Abstract][Full Text] [Related]
16. Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec-Liraglutide (Ideglira).
Zenari L; Da Porto A; De Moliner L; Lugli F; Guazzoni V; Groppelli G; Molteni L; Bracaccia M; Frison V; Simioni N; Bonsembiante B; Miranda C; Lapolla A
Diabetes Ther; 2021 Jan; 12(1):197-209. PubMed ID: 33104959
[TBL] [Abstract][Full Text] [Related]
17. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
Pei Y; Agner BR; Luo B; Dong X; Li D; Liu J; Liu L; Liu M; Lu Y; Nishida T; Xu X; Mu Y
Diabetes Obes Metab; 2021 Dec; 23(12):2687-2696. PubMed ID: 34387411
[TBL] [Abstract][Full Text] [Related]
18. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
[TBL] [Abstract][Full Text] [Related]
19. Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.
Abusnana S; Al Awadi F; Aly H; Bashier A; Kumar Dhanwal D; Halasa T; Jallo M; Medina J; Singhal S
Diabetes Res Clin Pract; 2023 Feb; 196():110183. PubMed ID: 36436550
[TBL] [Abstract][Full Text] [Related]
20. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
Krajnc M; Kravos Tramšek NA
Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
